Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 3Rectal Neoplasms 2Prostatic Neoplasms 2Leukemia 2Esophageal Neoplasms 2Colorectal Neoplasms 2Colonic Neoplasms 2Adenocarcinoma Of Esophagus 2Squamous Cell Carcinoma of Head and Neck 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Oligodendroglioma 1Neoplasms, Plasma Cell 1Multiple Myeloma 1Lung Neoplasms 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Head and Neck Neoplasms 1Gliosarcoma 1Glioma, Subependymal 1Glioma 1Glioblastoma 1Esophageal Squamous Cell Carcinoma 1Ependymoma 1Central Nervous System Neoplasms 1Cardiotoxicity 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms, Male 1Brain Neoplasms 1

Interventions

Doxorubicin 8Cyclophosphamide 4Docetaxel 3Atorvastatin 3dapagliflozin 2Trastuzumab 2Chemotherapy, Adjuvant 2Carvedilol 2nicotinamide-beta-riboside 1empagliflozin 1Tablets 1Reverse Transcriptase Polymerase Chain Reaction 1Radiotherapy 1Paclitaxel 1Neoadjuvant Therapy 1Methotrexate 1Metformin 1Mass Spectrometry 1Lisinopril 1Leucovorin 1Lapatinib 1Hydroxymethylglutaryl-CoA Reductase Inhibitors 1Gene Expression Profiling 1Fluorophotometry 1Filgrastim 1Fenofibrate 1Epirubicin 1Environmental Biomarkers 1Echocardiography 1Dexrazoxane 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Cardiotoxicity × Reverse Transcriptase Polymerase Chain Reaction × Clear all
NCT00436566 2022-08-05

Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery

Mayo Clinic

Phase 2 Completed
122 enrolled 22 charts
Breast

Breast Neoplasms, Breast Neoplasms, Male, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡